Immunotherapy, in particular, antibodies targeting CTLA4, PD-1 or PD-L1 led to partially spectacular treatment success in patients with several malignancies such as melanoma and non-small cell lung cancer (NSCLC) and renal cell carcinoma [3–6]. This evidence concerns the gene CTLA4 and non-small cell lung carcinoma.